US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Scribe Therapeutics, Inc.

29.74

+0.27000.92%

Post-market: 29.740.00000.00%16:10 EDT

Volume:141.19K

Turnover:4.25M

Market Cap:522.75M

PE:-2.26

High:31.00

Open:29.76

Low:29.02

Close:29.47

52wk High:39.60

52wk Low:17.31

Shares:17.58M

Float Shares:8.62M

Volume Ratio:0.82

T/O Rate:1.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-13.1763

EPS(LYR):-8.9776

ROE:--

ROA:--

PB:-3.17

PE(LYR):-3.31

Loading ...

Overview Company News Filings

Scribe Therapeutics Inc Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72)

Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate

Benzinga Earnings

Scribe Therapeutics Q2 FY26 Net Loss Narrows 34.34% to $6.5 Million; Revenue Falls 61.22% to $1.9 Million

Scribe Therapeutics - Q2 2026 Net Loss $6.50 Mln or $2.62 Per Share vs $9.90 Mln or $4.08 Per Share in Q2 2025

THOMSON REUTERS

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

THOMSON REUTERS

Scribe Therapeutics to Participate in Upcoming Investor Conferences

Scribe Therapeutics Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $60

THOMSON REUTERS

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Top Premarket Gainers

MT Newswires Live

Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)

Leerink starts Scribe Therapeutics at Outperform on X-editor platform

Scribe Therapeutics Inc Price Target Announced at $50.00/Share by Guggenheim

Guggenheim Initiates Scribe Therapeutics at Buy With $50 Price Target

MT Newswires Live

Leerink Partners Initiates Scribe Therapeutics at Outperform With $37 Price Target

MT Newswires Live

Wells Fargo Initiates Scribe Therapeutics at Overweight With $60 Price Target

MT Newswires Live

Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Scribe's Genetic Editing Aims to Prevent Heart Attacks

Insiders Double Down as Big Money Pours Into Scribe Therapeutics

OrbiMed Advisors Acquires 1,000,000 Scribe Therapeutics Shares Valued at $15 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/SCTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","market":"US","secType":"STK","nameCN":"Scribe Therapeutics, Inc.","latestPrice":29.74,"timestamp":1789156800000,"preClose":29.47,"halted":0,"volume":141192,"hourTrading":{"tag":"盘后","latestPrice":29.74,"preClose":29.74,"latestTime":"16:10 EDT","volume":1532,"amount":45300.760484,"timestamp":1789157405251,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00916185951815404,"floatShares":8623940,"shares":17577400,"eps":-13.17626,"marketStatus":"Post-Mkt","change":0.27,"latestTime":"09-11 17:39:28 EDT","open":29.76,"high":31,"low":29.0185,"amount":4252995,"amplitude":0.067238,"askPrice":31,"askSize":38,"bidPrice":29.61,"bidSize":78,"shortable":3,"etf":0,"ttmEps":-13.17626,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"listingDate":1784865600000,"exchange":"NASDAQ","adjPreClose":29.47,"preHourTrading":{"tag":"盘前","latestPrice":30.05,"preClose":29.47,"latestTime":"07:53 EDT","volume":2,"amount":59.55,"timestamp":1789127626396,"change":0.58,"changeRate":0.019681,"amplitude":0.018663},"postHourTrading":{"tag":"盘后","latestPrice":29.74,"preClose":29.74,"latestTime":"16:10 EDT","volume":1532,"amount":45300.760484,"timestamp":1789157405251,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.82215},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","floatShares":8623940,"roa":"--","roe":"--","lyrEps":-8.977559,"volumeRatio":0.82215,"shares":17577400,"dividePrice":0,"high":31,"amplitude":0.067238,"preClose":29.47,"low":29.0185,"week52Low":17.305,"pbRate":"-3.17","psRate":"15.70","week52High":39.6,"institutionHeld":0,"latestPrice":29.74,"committee":0.344828,"eps":-13.17626,"divideRate":0,"volume":141192,"delay":0,"ttmEps":-13.17626,"open":29.76,"prevYearClose":15,"prevWeekClose":28.67,"prevMonthClose":30.54,"prevQuarterClose":15,"fiveDayClose":30.81,"twentyDayClose":20.37,"sixtyDayClose":15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1788235200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SCTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SCTX","date":"2026-09-10","current":-2.236598,"percent":0.121212,"low":-19.666901,"twenty":-16.579857,"median":-13.571482,"eighty":-10.764262,"high":-6.340558,"avg":-13.604864,"sd":3.26575,"marketCap":556780708},"quantilePoints":[{"date":"2026-07-24","current":-7.393791,"twenty":-7.183144,"median":-6.867174,"eighty":-6.551205,"marketCap":264180150},{"date":"2026-07-31","current":-10.770598,"twenty":-10.0156,"median":-9.614342,"eighty":-7.393791,"marketCap":384833474},{"date":"2026-08-07","current":-13.41573,"twenty":-11.647029,"median":-10.284865,"eighty":-9.535147,"marketCap":479344048},{"date":"2026-08-14","current":-10.754759,"twenty":-12.565698,"median":-10.885431,"eighty":-9.693538,"marketCap":384267542},{"date":"2026-08-21","current":-17.333272,"twenty":-13.41573,"median":-11.187695,"eighty":-10.0156,"marketCap":619317792},{"date":"2026-08-28","current":-15.226669,"twenty":-16.393484,"median":-12.262115,"eighty":-10.284865,"marketCap":544048892},{"date":"2026-09-04","current":-16.266771,"twenty":-16.314288,"median":-13.162305,"eighty":-10.754759,"marketCap":581211732},{"date":"2026-09-10","current":-17.235658,"twenty":-16.579857,"median":-13.571482,"eighty":-10.764262,"marketCap":556780708}],"updateTime":1789131593237},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SCTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664879194","title":"Scribe Therapeutics Inc Price Target Maintained with a $60.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664879194?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:24","pubTimestamp":1788434640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SCTX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664588841","title":"Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664588841","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664588841?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:30","pubTimestamp":1788381015,"startTime":"0","endTime":"0","summary":"Reports Q2 revenue $1.92M, consensus $3.11M. “The second quarter and the weeks immediately following represented a transformational period for Scri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scribe-therapeutics-reports-q2-eps-2-62-consensus-3-72-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scribe-therapeutics-reports-q2-eps-2-62-consensus-3-72-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664284964","title":"Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2664284964","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664284964?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:10","pubTimestamp":1788379852,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics (NASDAQ:SCTX) reported quarterly losses of $(2.62) per share which missed the analyst consensus estimate of $(1.05) by 149.52 percent.  The company reported quarterly sales of $1.918 million which","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61589400/scribe-therapeutics-q3-eps-2-62-misses-1-05-estimate-sales-1-918m-miss-3-113m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664849504","title":"Scribe Therapeutics Q2 FY26 Net Loss Narrows 34.34% to $6.5 Million; Revenue Falls 61.22% to $1.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664849504","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664849504?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:09","pubTimestamp":1788379771,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics Q2 FY26 net loss narrows 34.34% to $6.5 million; revenue falls 61.22% to $1.9 millionScribe Therapeutics posted a Q2 net loss of USD 6.5 million, narrowing from USD 9.9 million a y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLbL8P2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664499648","title":"Scribe Therapeutics - Q2 2026 Net Loss $6.50 Mln or $2.62 Per Share vs $9.90 Mln or $4.08 Per Share in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2664499648","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664499648?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:05","pubTimestamp":1788379502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nTUAC20S0L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664361849","title":"Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2664361849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664361849?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:05","pubTimestamp":1788379502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nTUAC20S0L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856226","title":"Scribe Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856226","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856226?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"ALAMEDA, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR te","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354090/0/en/scribe-therapeutics-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX","SYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074889","title":"Scribe Therapeutics Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074889?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:10","pubTimestamp":1788171056,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nAZN4THCX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663020059","title":"U.S. Research Roundup-Adobe, Braveheart Bio, CACI International","url":"https://stock-news.laohu8.com/highlight/detail?id=2663020059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663020059?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:24","pubTimestamp":1788161046,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI InternationalAug 31 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adob","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4N44S0J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BURL","ADBE","BPOP","LUNR","ASST","BRCC","FTAG","CIEN","ETR","KALU","TPZ","PATH","RKLB","PTGX","ANF","SRE","XTL","AFRU","MDB","SCTX","CACI","RVMD","MADE","HQY","FIVN","HWAY","BILT","PCG","IBM","ATTO","BCDF","RBRK","HONA","EIX","SBRA","CRM","RDW","BRVE","DE","TROW","OHI","ICE","ATI","BAC","AFRM","BW","DLTR","PYPL","ADSK","AIRJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661734422","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661734422","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661734422?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:13","pubTimestamp":1787570029,"startTime":"0","endTime":"0","summary":"Sadot (SDOT) shares were up more than 52% in Monday's premarket activity following a 56% rise in Friday's session.Picard Medical (PMI) stock was 40% higher after a 5.9% increase at the prior closing w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SDOT","BK4209","LU0426412945.USD","SCTX","LU0545562505.USD","BK4139","LU0994945656.USD","HVII","BK4189","BK4082","LU0426417589.USD","LU1043141123.HKD","CYPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660233958","title":"Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660233958?lang=en_us&edition=fundamental","pubTime":"2026-08-20 23:00","pubTimestamp":1787238021,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Harrow Health (HROW) and Scribe Therapeutics Inc. (SCTX) wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-harrow-health-hrow-scribe-therapeutics-inc-sctx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-harrow-health-hrow-scribe-therapeutics-inc-sctx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","BK4141","BK4007","SCTX","HROW","BK4139","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660996594","title":"Leerink starts Scribe Therapeutics at Outperform on X-editor platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660996594","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660996594?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:10","pubTimestamp":1787073010,"startTime":"0","endTime":"0","summary":"As previously reported, Leerink initiated coverage of Scribe Therapeutics (SCTX) with an Outperform rating and $37 price target The firm views Scri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leerink-starts-scribe-therapeutics-at-outperform-on-x-editor-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leerink-starts-scribe-therapeutics-at-outperform-on-x-editor-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SOCL","SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467839","title":"Scribe Therapeutics Inc Price Target Announced at $50.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467839?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:32","pubTimestamp":1787056320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SCTX/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660699844","title":"Guggenheim Initiates Scribe Therapeutics at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2660699844","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660699844?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:25","pubTimestamp":1787048701,"startTime":"0","endTime":"0","summary":"(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660987469","title":"Leerink Partners Initiates Scribe Therapeutics at Outperform With $37 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2660987469","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660987469?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:24","pubTimestamp":1787048693,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Scribe Therapeutics at Outperform With $37 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660654484","title":"Wells Fargo Initiates Scribe Therapeutics at Overweight With $60 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2660654484","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660654484?lang=en_us&edition=fundamental","pubTime":"2026-08-18 17:33","pubTimestamp":1787045612,"startTime":"0","endTime":"0","summary":"Wells Fargo Initiates Scribe Therapeutics at Overweight With $60 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SCTX","PRTO","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660522468","title":"Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2660522468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660522468?lang=en_us&edition=fundamental","pubTime":"2026-08-18 16:15","pubTimestamp":1787040911,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Scribe Therapeutics (SCTX) with an Early-Stage Biotech rating. It believes STX-1150 “could have best of both wo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scribe-therapeutics-initiated-with-early-stage-biotech-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scribe-therapeutics-initiated-with-early-stage-biotech-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443465.HKD","BK4504","LU1791807156.HKD","LU0048573561.USD","BK4127","LU1868836591.USD","LU2471134523.USD","LU2265009873.SGD","LU0106831901.USD","LU0251142724.SGD","LU0868494708.USD","LU2237443895.HKD","BK4552","LU2237443382.USD","LU2750360641.GBP","BK4588","IE0004091025.USD","BK4516","LU0742534661.SGD","LU1668664300.SGD","LU1894683348.USD","LU2471134796.USD","LU0345770308.USD","IE00BSNM7G36.USD","LU1868837300.USD","IE00B19Z3581.USD","LU1868836757.USD","BK4550","IE0034235188.USD","LU0942090050.USD","XBI","SCTX","IE0004086264.USD","GSX","LU0251131958.USD","IE0002270589.USD","LU0868494617.USD","LU1804176565.USD","LU1868836914.USD","LU2237443622.USD","LU1868837136.USD","LU0345770993.USD","LU0096364046.USD","BK4139","LU1894683264.USD","LU2237438978.USD","LU2471134879.HKD","IE00BFXG1179.USD","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655744805","title":"Scribe's Genetic Editing Aims to Prevent Heart Attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2655744805","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655744805?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:26","pubTimestamp":1785421560,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe's one-time treatments can halv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU0058720904.USD","XLV","LU0006306889.USD","LU1201861249.SGD","LU1066053197.SGD","LU2125909247.SGD","LU1023059063.AUD","IHE","LU1861558580.USD","LU0689626769.HKD","FTXH","IE00BJT1NW94.SGD","LU1861559042.SGD","PPH","BK4007","RXL","LU2433249047.HKD","IXJ","LU2361044865.SGD","SCTX","IE0009355771.USD","JDOC","LU1035773651.USD","TRUH","SG9999014575.USD","ARKG","PAWZ","SG9999014559.SGD","LU1162221912.USD","BEAM","LU1941712264.USD","CRSP","IE00B4R5TH58.HKD","LU1066051225.USD","LU2360032135.SGD","MRK","VHT","PRME","LU0942090050.USD","IE00BBT3K403.USD","IYH","HRTS","LU0238689110.USD","IE00BN8TJ469.HKD","LU2023250843.SGD","LU1430594728.SGD","LU2112291526.USD","LU0203347892.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655846073","title":"Insiders Double Down as Big Money Pours Into Scribe Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2655846073","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655846073?lang=en_us&edition=fundamental","pubTime":"2026-07-30 10:02","pubTimestamp":1785376922,"startTime":"0","endTime":"0","summary":"New insider activity at Scribe Therapeutics Inc. ( ($SCTX) ) has taken place on July 29, 2026. Scribe Therapeutics Inc. has seen a wave of insider ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-big-money-pours-into-scribe-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-big-money-pours-into-scribe-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655810547","title":"OrbiMed Advisors Acquires 1,000,000 Scribe Therapeutics Shares Valued at $15 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655810547","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655810547?lang=en_us&edition=fundamental","pubTime":"2026-07-30 06:48","pubTimestamp":1785365280,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors acquires 1,000,000 Scribe Therapeutics shares valued at $15 millionOrbiMed Advisors, a Scribe Therapeutics director, reported an increase in indirect common-stock holdings to 1,348,825 shares.The filing shows the acquisition of 1 million common shares at USD 15.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL99fMsq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors Acquires 1,000,000 Scribe Therapeutics Shares Valued at $15 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}